Recombinant activated factor VII for intractable bleeding post splenectomy in a patient with myeloproliferative disorder.
Recombinant activated factor VII has been Food and Drug Administration approved to treat hemorrhages in hemophiliac patients with inhibitors and in acquired hemophilia patients. Recombinant activated factor VII use has also been considered for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities. The myeloproliferative disorders are a group of clonal hematologic diseases where, frequently, abnormal platelet function is considered a hallmark. This is the first case report addressing the clinical benefit of off-label use of recombinant activated factor VII in an attempt to control intractable bleeding in a patient with a myeloproliferative disorder after splenectomy.
El Kinge
Abdul Rahman D
AR
Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Mahfouz
Rami A
RA
Shamseddine
Ali I
AI
Taher
Ali T
AT
D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D001791:Blood Platelet Disorders / Q000188:drug therapy*; D015942:Factor VIIa / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications*; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D013156:Splenectomy / Q000009:adverse effects
D001779:Blood Coagulation Factors; D015942:Factor VIIa